Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health Part B step therapy Prior Auth …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentIndependent HealthPolicy N/A

    Step therapy criteria for Medicare Part B drugs

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy for Medicare Part B–covered drugs under Independent Health Medicare Advantage plans and describes provider requirements for coverage of specified Part B drugs (primarily applies to new therapy starts).

    Policy Summary
    PayerIndependent Health
    PolicyStep therapy criteria for Medicare Part B drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionDocument prior trial and inadequate response to the specified preferred comparator (or document intolerance/contraindication where allowed) for new-start requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+products listed
    new-start onlynew-start scope
    Medicare MA plansapplies to
    multiplebiosimilar rules noted

    Policy Overview

    This policy implements step therapy for specified Medicare Part B–covered drugs under Independent Health Medicare Advantage plans. For listed products, approval for a new start generally requires documentation that the patient previously tried and had an inadequate response to the named preferred comparator(s) (or has a documented intolerance or contraindication where the policy allows). Providers should submit prior authorization requests with clear documentation of the prior agent trial(s) and the clinical outcome to demonstrate the requirement is met.

    New starts definition — applicability
    Definition'New starts' are patients initiating therapy with the listed drug — the documented prior‑trial and step‑therapy requirements in this policy apply to these treatment initiations.
    ApplicabilityMost step‑therapy rules in this document explicitly apply to new starts only; continuation of an existing non‑preferred therapy is generally not subject to these new‑start requirements.
    Documentation requiredFor new starts, prior authorization must include documentation showing the patient tried and had an inadequate response to (or had a contraindication/intolerance to) the specified preferred comparator agent(s).
    ExceptionsRequirements do not apply when the patient is using the listed product for an indication not shared with the preferred comparator(s) (e.g., ophthalmic use of Avastin).

    Coverage Criteria by Drug / Product Group

    Intravitreal anti-VEGF step therapy (example: Eylea/Pavblu)

    For listed intravitreal products

    Bevacizumab prior trial: For approval, the patient must have tried and failed to have an adequate response to bevacizumab (Avastin).applies to new starts only

    Applies to the specified intravitreal products

    IVIG step therapy for Asceniv

    For Asceniv IVIG

    Prior IVIG trial: For approval, patient must have tried and failed to have a response to another intravenous immunoglobulin (IVIG) product.applies to new starts only

    Does not apply to indications not shared with preferred IVIG products

    Prior Authorization, Documentation, and Denial Risk

    Step Therapy

    Document prior trial and inadequate response (or intolerance/contraindication)

    For approval of the specified Part B drugs at new start, document that the patient tried and failed to have an adequate response to the named preferred alternative drug(s), or document intolerance/contraindication where the policy allows.

    • Applies to new starts only; many product-specific rules reference this general step-therapy requirement.
    • Intolerance or contraindication can substitute for a trial where explicitly permitted.
    Prior Authorization

    Document prior bevacizumab trial for intravitreal agents

    For approval of listed intravitreal agents, document that the patient tried and failed to have an adequate response to bevacizumab (Avastin).

    • Requirement applies to new starts only.
    • For Byooviz/Lucentis/Susvimo shared indications, also document failure of one additional anti‑VEGF as specified (Step 2).

    Step Therapy Tables and Operational Rules

    Coverage requirementNotes / scope
    Prior trial and inadequate response to the named preferred comparator (e.g., bevacizumab for intravitreal agents; Treanda for bendamustine products; gemcitabine for Avgemsi; other specified comparators)Applies to new therapy starts only; documentation must show prior trial and inadequate response (or documented intolerance/contraindication where allowed). Exclusions apply when the indication is not shared with the preferred comparator.
    Drug / StepRequired prior trial (new starts)
    Asceniv (intravenous immunoglobulin)Trial and inadequate response to another IVIG product; does not apply when Asceniv is used for an indication not shared with preferred IVIG products.
    Drugs (oncology bevacizumab group)Required prior trial (new starts)
    Alymsys / Avastin / Jobevne / Vegzelma (oncology indications)Trial and inadequate response to Mvasi or Zirabev. Does not apply to Avastin when used for ophthalmic (eye) indications or to indications not shared with Mvasi/Zirabev.
    Product groupRequired prior trial (new starts)
    Prolia and non-preferred Prolia denosumab biosimilarsTrial and inadequate response to Bildyos or Jubbonti (applies to new starts; exemption if indication not shared with comparators).
    Xgeva and non-preferred Xgeva denosumab biosimilarsTrial and inadequate response to Bilprevda or Wyost (applies to new starts; exemption if indication not shared with comparators).
    Requested agentRequired prior trial (new starts)
    Docivyx (J9172) / Beizray (J9174)Trial and inadequate response to docetaxel (J9171) is required for new starts.
    Requested agentRequired prior trial (new starts)
    KyxataTrial and inadequate response to carboplatin is required for new starts; does not apply to indications not shared with carboplatin.

    Biosimilar Preferences and Exceptions

    Billing Rule

    Document Mvasi or Zirabev trial for oncology bevacizumab biosimilars

    For oncology bevacizumab presentations (Alymsys, Avastin, Jobevne, Vegzelma) used for cancer indications, document prior trial and inadequate response to Mvasi or Zirabev before approval of the requested bevacizumab agent.

    • Requirement applies to new starts only.
    • Does not apply to ophthalmic Avastin or indications not shared with Mvasi/Zirabev.
    Billing Rule

    Document Bildyos or Jubbonti trial for Prolia requests

    For Prolia biosimilar or non‑preferred Prolia agent new starts, document prior trial and inadequate response to Bildyos or Jubbonti.

    • Requirement applies to new starts only.
    • Does not apply when indication is not shared with Bildyos or Jubbonti.

    Referenced HCPCS / J-Codes

    Referenced HCPCS/J-codes for bendamustine productsHCPCS
    J9036Bendamustine Apotex/Baxter (as cited for Belrapzo)
    J9034Bendeka (as cited for Belrapzo)
    J9056Vivimusta (as cited for Belrapzo)
    J9033Treanda (referenced comparator for bendamustine products)
    Chemotherapy HCPCS referencedHCPCS
    J9172Docivyx (per policy reference)
    J9174Beizray (per policy reference)
    J9171Docetaxel
    Pemetrexed and related J-codesHCPCS
    J9292Axtle (listed as J9292 in context)
    J9304Pemfexy (listed as J9304 in context)
    J9324Pemrydi RTU (listed as J9324 in context)
    J9294pemetrexed (preferred agent listed)
    J9296pemetrexed (preferred agent listed)
    J9297pemetrexed (preferred agent listed)
    J9305pemetrexed (preferred agent listed)
    J9314pemetrexed (preferred agent listed)
    J9322pemetrexed (preferred agent listed)
    J9323pemetrexed (preferred agent listed)

    Billing, Site of Care, and Medicare Part B Notes

    Billing Rule

    Bill viscosupplements through Medicare Part B (medical device)

    Viscosupplements are billed through Medicare Part B as medical devices and require medical prior authorization; providers must bill these products via Part B.

    • All viscosupplements require medical PA.
    • Non‑preferred viscosupplements require prior failure/intolerance to both Euflexxa and Synvisc‑One.
    Prior Authorization

    Require medical PA and prior‑failure proof for non‑preferred viscosupplements

    Medical prior authorization is required for all viscosupplements; submit prior‑failure documentation for Euflexxa and Synvisc‑One when requesting a non‑preferred viscosupplement.

    • Because viscosupplements are considered medical devices, they are billed through Medicare Part B.
    • Failure to document prior preferred‑agent trials may result in denial.

    For new starts of Vabysmo, prior authorization requires documentation of a trial and inadequate response to bevacizumab (Avastin). Because bevacizumab is commonly used off‑label intravitreally, clinicians should document prior intravitreal bevacizumab treatment when requesting Vabysmo for a Medicare Part B–billed ophthalmic injection.

    Initial (New-Start) Therapy Criteria

    inv cu-188: New-start step therapy — initial therapy requirements aggregated

    Initial therapy (new starts) requirements

    Comparator trial for new starts: New starts of several listed Part B drugs require a documented trial and inadequate response to a specified comparator drug (e.g., bevacizumab for intravitreal agents; Treanda for bendamustine products; gemcitabine for Avgemsi; other IVIGs for Asceniv).applies to new starts only

    See individual product entries for specifics

    inv cu-189: Bevacizumab initial therapy requirement

    Bevacizumab initial step: New-start patients must have prior trial/failure of Mvasi or Zirabev for oncology indications.new start

    Excludes ophthalmic and indications not shared with comparators

    Continuation of Therapy

    Documentation Required

    Include agent, dates, and outcome when documenting prior trials

    Documentation of prior trial and outcome (agent tried, dates, and whether response was inadequate or patient had intolerance/contraindication) is required for new starts and where product rules specify continuation documentation.

    • Applies broadly to product‑specific prior‑trial requirements.
    • Insufficient documentation may delay or cause denial.

    Policy Background and Scope

    Step therapy pairs a non‑preferred Part B drug with one or more preferred comparators; for many intravitreal products the specified preferred comparator is bevacizumab (Avastin). For approval of certain intravitreal agents as new starts, the policy requires documentation that the member tried and had an inadequate response to bevacizumab before higher‑cost alternatives will be authorized.

    Scope: This policy applies to Independent Health Medicare Advantage members and governs coverage and prior authorization requirements for specified Medicare Part B drugs. Clinicians requesting coverage must meet the documented prior‑trial and outcome requirements described in the product‑specific rules, and must indicate when an exception applies (for example, a non‑shared indication or documented contraindication).

    Policy Revision History

    2026-06-01policy_effective_dateLatest

    Policy content and step-therapy list effective as of 2026-06-01 (document current as of 6/1/2026).

    Policy Summary
    PayerIndependent Health
    PolicyStep therapy criteria for Medicare Part B drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionDocument prior trial and inadequate response to the specified preferred comparator (or document intolerance/contraindication where allowed) for new-start requests.
    SourceLink
    On This Page
    Policy OverviewCoverage Criteria by Drug / Product GroupPrior Authorization, Documentation, and Denial RiskStep Therapy Tables and Operational RulesBiosimilar Preferences and ExceptionsReferenced HCPCS / J-CodesBilling, Site of Care, and Medicare Part B NotesInitial (New-Start) Therapy CriteriaContinuation of TherapyPolicy Background and ScopePolicy Revision History
    ScopeApplies to the Part B drugs and biosimilars listed throughout this policy (step requirements and specific comparator agents are product‑specific and cited in each section).

    Step therapy is a utilization management approach that pairs a non-preferred Part B drug with one or more preferred comparator agents and requires a documented prior trial and inadequate response to the comparator before the non-preferred agent will be authorized. This document pairs Part B drugs with preferred comparators (for example, bevacizumab for many intravitreal anti‑VEGF agents, other IVIG products for Asceniv) and, in most cases, limits the requirement to patients initiating the listed drug (new starts). Clinical exceptions are recognized when documented intolerance or contraindication prevents use of the preferred agent.

    Oncology step therapy (Avgemsi)

    For Avgemsi oncology use

    Gemcitabine prior trial: For approval of Avgemsi, the patient must have tried and failed to have an adequate response to intravenous gemcitabine.applies to new starts only

    Does not apply to indications not shared by intravenous gemcitabine

    Bendamustine product step therapy

    For Belrapzo / bendamustine alternatives

    Treanda prior trial: For approval of Belrapzo/bendamustine Apotex/Baxter, Bendeka, or Vivimusta, the patient must have tried and failed to have an adequate response to Treanda (J9033), unless contraindicated or not tolerated.applies to new starts only

    Does not apply to indications not shared with Treanda

    HIV PrEP/related agent requirement (Apretude)

    For Apretude

    TDF/FTC intolerance or contraindication: For approval, patient must have tried and had an intolerance to or has a contraindication to emtricitabine/tenofovir disoproxil fumarate.

    Intolerance/contraindication may be used in lieu of trial where specified

    Oncology bevacizumab biosimilar step therapy

    For oncology bevacizumab-class products

    Mvasi/Zirabev prior trial: For approval of Alymsys, Avastin, Jobevne, or Vegzelma for oncology indications, the patient must have tried and failed to have an adequate response to Mvasi or Zirabev.applies to new starts only

    Does not apply to ophthalmic Avastin uses or indications not shared with Mvasi/Zirabev

    Alymsys/Avastin/Jobevne/Vegzelma — Oncology

    Covered when ALL of the following are met for oncology bevacizumab products (new starts only):

    Bevacizumab oncology prior trial: Patient has tried and failed to have an adequate response to Mvasi or Zirabev.new start

    Does not apply to ophthalmic indications or to indications not shared by Mvasi or Zirabev

    Myobloc — coverage when ALL of the following are met (new starts only)

    Covered when ALL of the following are met (new starts only):

    Myobloc prior trial: Patient has tried and failed to have an adequate response to Botox and Xeomin.new start

    Kyxata — coverage when ALL of the following are met (new starts only)

    Covered when ALL of the following are met (new starts only):

    Kyxata prior carboplatin: Patient has tried and failed to have an adequate response to carboplatin.new start

    Does not apply to indications not shared by carboplatin

    Docivyx and Beizray — coverage when ALL of the following are met (new starts only)

    Covered when ALL of the following are met (new starts only):

    Docivyx/Beizray prior docetaxel: Patient has tried and failed to have an adequate response to docetaxel (J9171).new start

    Denosumab products and biosimilars

    Covered when ALL of the following are met for denosumab products (new starts only):

    Prolia and denosumab biosimilars prior: Patient has tried and failed to have an adequate response to Bildyos or Jubbonti for Prolia or its non-preferred biosimilars.new start

    Does not apply to indications not shared with Bildyos or Jubbonti

    Xgeva and denosumab biosimilars prior: Patient has tried and failed to have an adequate response to Bilprevda or Wyost for Xgeva or its non-preferred biosimilars.new start

    Does not apply to indications not shared with Bilprevda or Wyost

    NMOSD and generalized myasthenia gravis biologic prior therapy

    Covered when ALL of the following are met (new starts only):

    NMOSD prior agents: For NMOSD, patient has tried and failed to have an adequate response to or had an intolerance/contraindication to Enspryng and either Uplizna or rituximab.new start
    gMG prior agents: For generalized myasthenia gravis, patient has tried and failed to have an adequate response to or had an intolerance/contraindication to Vyvgart or Vyvgart Hytrulo.new start

    Enjaymo prior rituximab requirement

    Covered when ALL of the following are met (new starts only):

    Enjaymo prior rituximab: Patient has tried and failed to have an adequate response to Ruxience or Riabni (or another rituximab product).new start

    Briumvi — coverage when ALL of the following are met (new starts only)

    Covered when ALL of the following are met (new starts only):

    Briumvi prior ocrelizumab: Patient has tried and failed to have an adequate response to Ocrevus.new start

    Ruxience / Riabni requirement

    For approval (new starts)

    Rituximab biosimilars: Patient must have tried and failed to have an adequate response to Ruxience or Riabni (or another rituximab product).new starts only

    applies only to new starts

    Retacrit requirement

    For approval (new starts)

    Retacrit trial: Patient must have tried and failed to have an adequate response to Retacrit. Does not apply to patients using Epogen or Procrit for indications not shared with Retacrit.new starts only

    applies only to new starts

    Evkeeza requirement

    For approval (new starts)

    Evkeeza prior therapy: Patient must have tried and failed to have an adequate response to or have a contraindication to both a maximally-tolerated dose of a statin and a PCSK9 inhibitor.new starts only

    sourced from policy detail

    Zarxio requirement

    For approval (new starts)

    Zarxio trial: Patient must have tried and failed to have an adequate response to Zarxio. Does not apply to patients using a non-preferred agent for any indication not shared with Zarxio.new starts only

    Applies to listed G-CSF agents

    Ilumya requirement

    For approval (new starts)

    Ilumya prior biologics: Patient must have tried and failed to have an adequate response to or had an intolerance to at least the formulary-preferred IL-17 inhibitor (Cosentyx) AND one of the following: generic infliximab or Remicade or one other on-formulary biologic agent for psoriasis (including on-formulary adalimumab biosimilars, Enbrel, Humira, Skyrizi, on-formulary ustekinumab biosimilars).new starts only

    sourced from policy detail

    Imjudo requirement

    For approval (non-small cell lung cancer)

    Imjudo prior Libtayo: For NSCLC approval, patient must have had an adequate response to or had an intolerance/contraindication to regimens containing cemiplimab (Libtayo).new starts only

    sourced from policy detail

    Avsola/Inflectra/Renflexis requirement

    For approval (new starts)

    Infliximab biosimilars: Patient must have tried and failed to have an adequate response to generic infliximab or Remicade. Does not apply to indications not shared with those agents.new starts only

    Applies to Avsola, Inflectra, Renflexis

    Inlexzo requirement

    For approval (new starts)

    Inlexzo prior gemcitabine: Patient must have tried and failed to have an adequate response to intravesical gemcitabine. Does not apply to indications not shared with intravesical gemcitabine.new starts only

    Invega Hafyera requirement

    For approval (new starts)

    Invega Hafyera prior injections: Documentation of at least 4 months' treatment with 1-month paliperidone palmitate extended-release injectable suspension OR at least one 3-month injection of 3-month paliperidone palmitate extended-release injectable suspension is required.4 months or 1 three-month injection

    Applies to new starts only

    Feiba requirement

    For approval (new starts)

    Feiba prior Hemlibra: Patient must have tried and failed to have an adequate response to Hemlibra. This requirement does not apply to treatment of hemophilia B.new starts only

    Invega Hafyera Initial Therapy

    Covered when ALL of the following are met for new starts

    Invega Hafyera prior treatment: Documentation of at least 4 months' treatment with 1-month paliperidone palmitate extended-release injectable suspension OR at least one 3-month injection of 3-month paliperidone palmitate extended-release injectable suspension.4 months or 1 three-month injection

    Applies to new starts only

    Invega Trinza Initial Therapy

    Covered when ALL of the following are met for new starts

    Invega Trinza prior treatment: Documentation of at least 4 months' treatment with 1-month paliperidone palmitate extended-release injectable suspension.4 months

    Applies to new starts only

    Khapzory Initial Therapy

    Covered when ALL of the following are met for new starts

    Khapzory prior treatment: Patient must have tried and failed to have an adequate response to generic leucovorin.trial and inadequate response

    Applies to new starts only; does not apply when patient uses levoleucovorin for an indication not shared with leucovorin

    Factor VIII Products Initial Therapy

    Covered when ALL of the following are met for new starts

    Adynovate/Eloctate/Esperoct prior treatment: Patient must have tried and failed to have an adequate response to Jivi.trial and inadequate response to Jivi

    Applies to new starts only

    Tysabri Initial Therapy

    Covered when ALL of the following are met for new starts

    Tysabri prior treatment: Patient must have tried and failed to have an adequate response to Tyruko (natalizumab-sztn).trial and inadequate response

    Applies to new starts only; does not apply to indications not shared with Tyruko

    Opdualag Initial Therapy

    Covered when ALL of the following are met for new starts

    Opdualag prior treatment: Patient must have tried and failed to have an adequate response to Opdivo plus Yervoy OR have a contraindication to Yervoy.trial and inadequate response or contraindication

    Applies to new starts only

    Abraxane Initial Therapy

    Covered when ALL of the following are met for new starts

    Abraxane prior treatment: For indications other than pancreatic cancer or small bowel carcinoma, patient must have tried and failed generic paclitaxel.trial and inadequate response to generic paclitaxel

    Applies to new starts only; does not apply for indications not shared with generic paclitaxel

    Pegfilgrastim Biosimilars Initial Therapy

    Covered when ALL of the following are met for new starts

    Non-preferred pegfilgrastim/Ryzneuta prior treatment: Patient must have tried and failed to have an adequate response to Udenyca.trial and inadequate response to Udenyca

    Applies to new starts only; does not apply for indications not shared with preferred pegfilgrastim products

    Pemetrexed Products Initial Therapy

    Covered when ALL of the following are met for new starts

    Axtle/Pemfexy/Pemrydi prior treatment: Patient must have tried and failed to have an adequate response to one of the listed pemetrexed drugs (J9294, J9296, J9297, J9305, J9314, J9322, J9323) unless contraindicated or not tolerated.trial and inadequate response to preferred pemetrexed agent

    Applies to new starts only

    Intravitreal anti-VEGF — Cimerli/ranibizumab-eqrn

    Covered when ALL of the following are met (intravitreal products):

    Intravitreal anti-VEGF (Cimerli/ranibizumab-eqrn): For approval of Cimerli or ranibizumab-eqrn, the patient must have tried and failed to have an adequate response to bevacizumab (Avastin).new starts only

    Applies to new starts only

    Byooviz / Lucentis / Susvimo step-therapy

    Covered when ALL of the following are met (Byooviz, Lucentis, Susvimo for shared indications):

    Step 1: Trial and inadequate response to bevacizumab (Avastin).new starts only

    Step 1

    Step 2: Trial and inadequate response to one additional anti-VEGF: Cimerli or ranibizumab-eqrn, aflibercept (Eylea/Eylea HD), brolucizumab (Beovu), or faricimab (Vabysmo).new starts only

    Step 2

    Rituximab products

    Covered when ALL of the following are met (rituximab agents):

    Rituximab biosimilars: For approval of Rituxan, Rituxan Hycela, or Truxima, the patient must have tried and failed to have an adequate response to Riabni or Ruxience.new starts only

    Does not apply when indication is not shared with Riabni or Ruxience

    Rystiggo

    Covered when ALL of the following are met (Rystiggo):

    Generalized myasthenia gravis (anti-AChR antibody-positive): Patient must have tried and failed to have an adequate response to or had an intolerance/contraindication to Vyvgart or Vyvgart Hytrulo.new starts only

    Applies to new starts only

    Rytelo

    Covered when ALL of the following are met (Rytelo):

    Myelodysplastic syndrome criteria: Patient must have tried and failed or had an intolerance/contraindication to Reblozyl when MDS meets the specified IPSS-R and ring sideroblast/EPO criteria.new starts only

    Detailed MDS subcriteria present in source

    Spinraza

    Covered when ALL of the following are met (Spinraza):

    Spinal muscular atrophy therapy sequencing: Patient must have tried and failed to have an adequate response to or had an intolerance/contraindication to Evrysdi.new starts only

    Applies to new starts only

    Tezspire

    Covered when ANY of the following are met (Tezspire):

    Severe asthma prior biologic failure: Tried and failed, was intolerant to, or had a contraindication to dupilumab plus one other biologic for severe asthma (IL-5 antagonist, IL-5 receptor antagonist, or omalizumab).new starts only

    Option 1

    Eosinophil count below that required to use the other medications.new starts only

    Option 2

    Actemra / Tocilizumab biosimilars

    Covered when ALL of the following are met (Actemra / non-preferred tocilizumab biosimilars):

    Tocilizumab biosimilars: Patient must have tried and failed to have an adequate response to Tyenne or tocilizumab-aazg.new starts only

    Does not apply when indication is not shared with the preferred agents

    Herceptin / Trastuzumab biosimilars

    Covered when ALL of the following are met (Herceptin / trastuzumab biosimilars):

    Trastuzumab biosimilars: Patient must have tried and failed to have an adequate response to Kanjinti or Trazimera.new starts only

    Does not apply when indication is not shared with the preferred agents

    Herceptin / trastuzumab biosimilars — new-start specifics

    Herceptin and trastuzumab biosimilars (new starts)

    Prior failure requirement: Patient must have tried and failed to have an adequate response to Kanjinti or Trazimera.new starts only

    Does not apply when indication is not shared by Kanjinti or Trazimera

    Ultomiris GMG requirement

    Ultomiris (generalized myasthenia gravis, new starts)

    Prior therapy requirement: Patient must have tried and failed to have an adequate response to or had an intolerance/contraindication to Vyvgart or Vyvgart Hytrulo.new starts only

    Uplizna indications-specific requirements

    Uplizna (NMOSD and gMG, new starts)

    NMOSD prior therapy requirement: For NMOSD, patient must have tried and failed to have an adequate response to or had an intolerance/contraindication to Enspryng.new starts only
    gMG prior therapy requirement: For generalized myasthenia gravis, patient must have tried and failed to have an adequate response to or had an intolerance/contraindication to Rystiggo (rozanolixizumab).new starts only

    Stelara / ustekinumab biosimilabls

    Stelara / ustekinumab biosimilars (new starts)

    Prior therapy requirement: Patient must have tried and failed to have an adequate response to Selarsdi or Yesintek.new starts only

    Does not apply when indication is not shared by Selarsdi or Yesintek

    Vabysmo requirement

    Vabysmo (new starts)

    Prior therapy requirement: Patient must have tried and failed to have an adequate response to bevacizumab (Avastin).new starts only

    Viscosupplement step therapy

    Viscosupplements (non-preferred, new starts)

    Prior therapy requirement: Patient must have tried and failed to have an adequate response to or had an intolerance to both preferred agents (Euflexxa, Synvisc-One).new starts only

    All viscosupplements require medical prior authorization and are billed through Medicare Part B as devices

    Vyepti requirement

    Vyepti (new starts)

    Prior therapy requirement: Patient must have tried and failed to have an adequate response to any two oral agents used to prevent/reduce frequency of migraines and have had prior use of one injectable CGRP antagonist/receptor antagonist.new starts only

    Vyvgart Hytrulo requirement

    Vyvgart Hytrulo (new starts)

    Prior therapy requirement: Patient must have failed to respond to therapy with at least two of the following drug groups: acetylcholinesterase inhibitors, corticosteroids, nonsteroidal immunosuppressive therapies (e.g., methotrexate, azathioprine, mycophenolate, cyclosporine).new starts only

    Zilretta requirement

    Zilretta (new starts)

    Prior therapy requirement: Patient must have tried and failed to have an adequate response to at least one other injectable corticosteroid.new starts only

    Initial Therapy (new starts)

    Covered when ALL of the following are met (for new starts):

    Step requirement: Patient has tried and failed to have an adequate response to at least one specified preferred comparator drug per product-specific rules (e.g., bevacizumab for intravitreal agents; Riabni/Ruxience for rituximab-class agents).applies to new starts only

    See individual product-specific entries for exact comparators and exceptions

    Step therapy requirements do not apply when the patient is using the requested product for an indication that is not shared with the preferred comparator(s). In those cases the prior‑trial requirement is waived and the clinician should document the indication to support coverage.

    The requirement to trial Mvasi or Zirabev does not apply when bevacizumab (Avastin) is being used for ophthalmic (intravitreal) indications. For intravitreal uses, the intravitreal anti‑VEGF step rules (which start with bevacizumab) govern authorization instead.

    The carboplatin prior‑trial requirement for Kyxata is limited to indications shared by carboplatin; if Kyxata is requested for an indication not shared with carboplatin the prior‑trial requirement does not apply. Providers should indicate the specific diagnosis when requesting authorization.

    Prior‑trial requirements for denosumab biosimilars (Prolia/Xgeva and non‑preferred biosimilars) do not apply when the denosumab agent is used for an indication not shared with the named comparators (Bildyos/Jubbonti for Prolia; Bilprevda/Wyost for Xgeva). Document the indication to support an exception.

    The requirement to trial Retacrit before initiating listed erythropoiesis‑stimulating agents applies to new starts only and is waived when the patient is using Epogen or Procrit for an indication not shared with Retacrit. Prior‑trial documentation or reason for exemption must be included in the request.

    The Zarxio (filgrastim biosimilar) trial requirement for listed G‑CSF agents does not apply when the non‑preferred agent is being used for an indication not shared with Zarxio. Include the indication in the prior authorization documentation when seeking an exception.

    Infliximab biosimilar step requirements (Avsola/Inflectra/Renflexis) are limited to shared indications: the prior trial of generic infliximab or Remicade is not required when the requested infliximab‑class agent is being used for an indication not shared with those comparators. State the indication on the authorization request to support the exception.

    The Inlexzo prior‑trial requirement (intravesical gemcitabine) does not apply when Inlexzo is used for an indication not shared with intravesical gemcitabine. Providers should document the indication to establish applicability.

    The Feiba requirement (prior trial of Hemlibra) applies to new starts only and explicitly does not apply to treatment of hemophilia B. When requesting Feiba for hemophilia B, indicate the diagnosis to avoid unnecessary step‑therapy denial.

    Patients using levoleucovorin are exempt from the Khapzory (leucovorin) prior‑trial requirement when the indication for levoleucovorin is not shared with generic leucovorin. Document the indication to support the exemption.

    The Tysabri prior‑trial requirement (trial and inadequate response to Tyruko) does not apply when Tysabri is used for an indication not shared with Tyruko. Providers should document the diagnosis on the prior authorization request.

    The rituximab step requirement (prior trial and inadequate response to Riabni or Ruxience) is waived when a rituximab agent is being used for an indication not shared with Riabni or Ruxience. Include indication details in the authorization to demonstrate applicability.

    Step requirements for tocilizumab (Actemra or non‑preferred biosimilars) and trastuzumab (Herceptin/other trastuzumab biosimilars) do not apply when the non‑preferred agent is used for an indication not shared with the preferred comparator biosimilars. Document the indication to support exemption.

    Prior Authorization

    Document prior IVIG trial for Asceniv

    For new starts of Asceniv, document a prior trial and inadequate response to another IVIG product (or show the indication is not shared with preferred IVIGs).

    • Requirement applies to new starts only.
    • Exemption when Asceniv is used for an indication not shared with preferred IVIG products.
    Prior Authorization

    Document prior docetaxel (J9171) trial

    For requests for Docivyx (J9172) or Beizray (J9174), document prior use of docetaxel (J9171) with inadequate response.

    • This prior-docetaxel requirement applies to new starts only.
    Prior Authorization

    Document prior carboplatin trial for Kyxata

    For Kyxata new starts, document a prior trial and inadequate response to carboplatin (unless the requested indication is not shared with carboplatin).

    • Requirement applies to new starts only.
    • Does not apply when Kyxata is used for an indication not shared by carboplatin.
    Prior Authorization

    Document prior Ruxience or Riabni trial for rituximab products

    For new starts of rituximab products (e.g., Rituxan, Rituxan Hycela, Truxima, Enjaymo), document prior trial and inadequate response to Ruxience or Riabni (or another rituximab biosimilar).

    • Requirement applies to new starts only.
    • Exemption when the patient is using a rituximab agent for an indication not shared with Riabni/Ruxience.
    Prior Authorization

    Document Retacrit trial for ESA approvals

    For listed erythropoiesis‑stimulating agents, new starts require documentation of trial and inadequate response to Retacrit (unless the member uses Epogen/Procrit for an indication not shared with Retacrit).

    • Requirement applies to new starts only.
    • Exemption when indication is not shared with Retacrit.
    Prior Authorization

    Document statin + PCSK9 trial or contraindication for Evkeeza

    For Evkeeza new starts, document trial and inadequate response to, or contraindication to, both a maximally‑tolerated statin and a PCSK9 inhibitor.

    • Requirement applies to new starts only.
    • Contraindication may be documented instead of trial where specified.
    Prior Authorization

    Document Zarxio trial for G‑CSF agents

    For Filkri/Granix/Neupogen/Nivestym/Nypozi/Releuko new starts, document prior trial and inadequate response to Zarxio.

    • Requirement applies to new starts only.
    • Does not apply when the member is using a non‑preferred agent for an indication not shared with Zarxio.
    Prior Authorization

    Document trial/failure of preferred IL‑17 inhibitor and one biologic for Ilumya

    For Ilumya new starts, document trial and failure or intolerance to the formulary‑preferred IL‑17 inhibitor (Cosentyx) and one of the listed on‑formulary biologics as specified.

    • Requirement applies to new starts only.
    Prior Authorization

    Document prior cemiplimab (Libtayo) response/intolerance for Imjudo

    For Imjudo in NSCLC, document prior adequate response to or intolerance/contraindication to cemiplimab (Libtayo).

    • Requirement applies to new starts only.
    • Intolerance or contraindication to cemiplimab may be used in lieu of prior response when specified.
    Prior Authorization

    Document intravesical gemcitabine trial for Inlexzo

    For Inlexzo new starts, document prior trial and inadequate response to intravesical gemcitabine (or show the indication is not shared).

    • Requirement applies to new starts only.
    • Does not apply when Inlexzo is used for an indication not shared by intravesical gemcitabine.
    Documentation Required

    Document paliperidone palmitate prior treatment for Invega Hafyera

    For Invega Hafyera new starts, provide documentation of prior paliperidone palmitate treatment: at least 4 months of 1‑month dosing or at least one 3‑month paliperidone palmitate injection.

    • This documentation requirement applies to new starts only.
    Documentation Required

    Document 4 months' 1‑month paliperidone palmitate prior treatment for Trinza

    For Invega Trinza new starts, document at least 4 months' prior treatment with 1‑month paliperidone palmitate.

    • Requirement applies to new starts only.
    Prior Authorization

    Document generic leucovorin trial for Khapzory

    For Khapzory new starts, document trial and inadequate response to generic leucovorin (unless the member uses levoleucovorin for an indication not shared).

    • Requirement applies to new starts only.
    • Exemption when indication is not shared with leucovorin.
    Prior Authorization

    Document Jivi trial for hemophilia products

    For Adynovate, Eloctate, or Esperoct new starts, document trial and inadequate response to Jivi.

    • Requirement applies to new starts only.
    • Does not apply to treatment of hemophilia B per policy exception.
    Prior Authorization

    Document Tyruko trial for Tysabri

    For Tysabri new starts, document trial and inadequate response to Tyruko (natalizumab‑sztn) or show the indication is not shared with Tyruko.

    • Requirement applies to new starts only.
    • Exemption when indication is not shared with Tyruko.
    Prior Authorization

    Document Opdivo+Yervoy trial or Yervoy contraindication for Opdualag

    For Opdualag new starts, document trial and inadequate response to Opdivo plus Yervoy or document a contraindication to Yervoy.

    • Requirement applies to new starts only.
    • Absence of Yervoy due to contraindication must be documented.
    Prior Authorization

    Document generic paclitaxel trial for Abraxane

    For Abraxane new starts (except pancreatic cancer or small bowel carcinoma), document prior trial and inadequate response to generic paclitaxel.

    • Requirement applies to new starts only.
    • Does not apply for indications not shared with generic paclitaxel.
    Prior Authorization

    Document Udenyca trial for pegfilgrastim approvals

    For non‑preferred pegfilgrastim biosimilars or Ryzneuta new starts, document trial and inadequate response to Udenyca.

    • Requirement applies to new starts only.
    • Does not apply for indications not shared with preferred pegfilgrastim products.
    Prior Authorization

    Document trial of preferred pemetrexed (listed J‑codes)

    For Axtle, Pemfexy, or Pemrydi new starts, document trial and inadequate response to a preferred pemetrexed agent (listed J‑codes) unless contraindicated or not tolerated.

    • Requirement applies to new starts only.
    • Preferred comparator J‑codes are listed in the policy's coding section.
    Prior Authorization

    Document bevacizumab trial (and additional anti‑VEGF where required) for intravitreal agents

    For intravitreal anti‑VEGF products (Cimerli, ranibizumab‑eqrn) new starts, document prior trial and inadequate response to bevacizumab (Avastin); for Byooviz/Lucentis/Susvimo shared indications, also document failure of an additional anti‑VEGF per the two‑step rule.

    • All intravitreal anti‑VEGF step requirements apply to new starts only.
    • Failure to document these prior trials may result in denial.
    Prior Authorization

    Document Riabni or Ruxience trial for Rituxan/Truxima requests

    For Rituxan, Rituxan Hycela, or Truxima new starts, document prior failure of Riabni or Ruxience (preferred rituximab biosimilars) before requesting the non‑preferred product.

    • Requirement applies to new starts only.
    • Document indication‑specific exemptions where the indication is not shared with Riabni/Ruxience.
    Billing Rule

    Obtain medical PA and bill viscosupplements via Medicare Part B

    All viscosupplements require medical prior authorization; because they are considered medical devices, bill them through Medicare Part B.

    • Non‑preferred viscosupplements require prior failure or intolerance to both Euflexxa and Synvisc‑One before approval.
    • This billing rule applies to new starts only where step criteria are specified.
    Prior Authorization

    Submit PA with product‑specific step/failure documentation

    Products listed in the Part B section require prior authorization and are subject to the product‑specific step/failure criteria described in the policy details; providers must submit documentation of prior trials and outcomes when requesting authorization.

    • This statement covers the multiple Part B products enumerated in the policy.
    • Failure to include required prior‑trial documentation may cause denial.
    Prior Authorization

    Document prior injectable corticosteroid trial for new starts

    For new starts of injectable corticosteroid therapies, document trial and inadequate response to at least one other injectable corticosteroid.

    • This requirement applies to new starts only.
    • Failure to document a prior injectable corticosteroid trial may trigger denial.
    Denial Risk

    Denial risk if prior trial and outcome not documented

    Requests for new‑start coverage may be denied if the provider does not document the required prior trial(s) and the clinical outcome (inadequate response or intolerance/contraindication) for the named comparator(s).

    • Denial risk highlighted for intravitreal anti‑VEGF agents (no prior bevacizumab documented).
    • Denial risk also cited for multiple product groups when required prior trials are not shown.
    Documentation Required

    Document prior trial details: agent, dates, and outcome

    Always include documentation showing the prior agent tried, the dates of therapy, and the outcome (inadequate response, intolerance, or contraindication) when requesting prior authorization for a new start.

    • This documentation requirement applies to new starts and to continuation where specified by product rules.
    • Insufficient documentation of dates or outcomes may delay or cause denial.
    Indication groupRequired prior agents (new starts)
    Neuromyelitis optica spectrum disorder (NMOSD)Trial and inadequate response to or intolerance/contraindication to Enspryng AND either Uplizna or rituximab (applies to new starts).
    Generalized myasthenia gravis (gMG)Trial and inadequate response to or intolerance/contraindication to Vyvgart or Vyvgart Hytrulo (applies to new starts).
    Rituximab product groupRequired prior trial (new starts)
    Rituxan / Rituxan Hycela / Truxima (and other rituximab products)Patient must have tried and failed to have an adequate response to preferred rituximab biosimilars Riabni or Ruxience (or another rituximab product) prior to approval for new starts.
    ESA agentsRequired prior trial (new starts)
    Listed ESAs (e.g., Epogen / Procrit presentations referenced)Trial and inadequate response to Retacrit is required for new starts; does not apply when patient is using Epogen or Procrit for an indication not shared with Retacrit.
    G-CSF agentsRequired prior trial (new starts)
    Filkri / Granix / Neupogen / Nivestym / Nypozi / Releuko (listed G-CSF agents)Trial and inadequate response to Zarxio is required for new starts; does not apply to indications not shared with Zarxio.
    Infliximab biosimilarsRequired prior trial (new starts)
    Avsola / Inflectra / RenflexisTrial and inadequate response to generic infliximab or Remicade is required for new starts; does not apply to indications not shared with those agents.
    ProductRequired prior treatment (new starts)
    Invega HafyeraDocumentation of at least 4 months' treatment with 1‑month paliperidone palmitate OR at least one 3‑month paliperidone palmitate injection is required for new starts.
    ProductRequired prior treatment (new starts)
    Invega TrinzaDocumentation of at least 4 months' treatment with 1‑month paliperidone palmitate is required for new starts.
    ProductRequired prior trial (new starts)
    KhapzoryTrial and inadequate response to generic leucovorin is required for new starts; does not apply when indication is not shared with leucovorin (e.g., levoleucovorin users).
    Hemophilia productsRequired prior trial (new starts)
    Adynovate / Eloctate / EsperoctTrial and inadequate response to Jivi is required for new starts.
    ProductRequired prior trial (new starts)
    Tysabri (natalizumab)Trial and inadequate response to Tyruko (natalizumab‑sztn) is required for new starts; does not apply to indications not shared with Tyruko.
    Product groupRequired prior trial (new starts)
    Non‑preferred pegfilgrastim biosimilars or RyzneutaTrial and inadequate response to Udenyca is required for new starts; does not apply to indications not shared with preferred pegfilgrastim products.
    Requested pemetrexed productsRequired prior trial (new starts)
    Axtle (J9292) / Pemfexy (J9304) / Pemrydi RTU (J9324)Trial and inadequate response to a preferred pemetrexed agent (one of the listed J‑codes: J9294, J9296, J9297, J9305, J9314, J9322, J9323) is required for new starts unless contraindicated or not tolerated.
    Intravitreal agentsStep therapy requirement (new starts)
    Cimerli / ranibizumab‑eqrnStep 1: trial and inadequate response to bevacizumab (Avastin) is required for new starts.
    Byooviz / Lucentis / Susvimo (shared indications)Step 1: trial and inadequate response to bevacizumab (Avastin); Step 2: trial and inadequate response to one additional anti‑VEGF (Cimerli/ranibizumab‑eqrn, aflibercept/Eylea, brolucizumab/Beovu, or faricimab/Vabysmo) — both steps apply to new starts.
    Intravitreal shared‑indication agentsSecond‑step requirement (new starts)
    Byooviz / Lucentis / Susvimo (for shared indications)After Step 1 failure of bevacizumab (Avastin), a second‑step trial and inadequate response to one additional anti‑VEGF (Cimerli/ranibizumab‑eqrn, aflibercept/Eylea, brolucizumab/Beovu, or faricimab/Vabysmo) is required for new starts.
    Requested rituximab productsRequired prior trial (new starts)
    Rituxan / Rituxan Hycela / TruximaPatient must have tried and failed to have an adequate response to Riabni or Ruxience for new starts; does not apply when indication is not shared with these biosimilars.
    Viscosupplement statusRequired prior trial (new starts)
    Non‑preferred viscosupplements (e.g., any listed other than Euflexxa or Synvisc‑One)Patient must have tried and failed to have an adequate response to BOTH preferred viscosupplements (Euflexxa and Synvisc‑One) before approval; all viscosupplements require medical prior authorization and are billed through Medicare Part B.
    Injectable corticosteroid productsRequired prior trial (new starts)
    Non‑preferred injectable corticosteroids (new starts)Patient must have tried and failed to have an adequate response to at least one other injectable corticosteroid for approval of a new start.
    Billing Rule

    Document Bilprevda or Wyost trial for Xgeva requests

    For Xgeva biosimilar or non‑preferred Xgeva agent new starts, document prior trial and inadequate response to Bilprevda or Wyost.

    • Requirement applies to new starts only.
    • Does not apply when indication is not shared with Bilprevda or Wyost.
    Billing Rule

    Require Ruxience or Riabni trial before other rituximab products

    For other rituximab product new starts, document trial and inadequate response to Ruxience or Riabni (preferred rituximab biosimilars) before approval of non‑preferred rituximab agents.

    • Requirement applies to new starts only.
    • Exemption when indication is not shared with the preferred biosimilars.
    Billing Rule

    Require Retacrit trial for Epogen/Procrit new starts

    For Epogen or Procrit new starts, document trial and inadequate response to Retacrit before requesting the non‑preferred ESA.

    • Requirement applies to new starts only.
    • Does not apply when the patient's indication is not shared with Retacrit.
    Billing Rule

    Require Zarxio trial for listed G‑CSF agents

    For Filkri, Granix, Neupogen, Nivestym, Nypozi, or Releuko new starts, document trial and inadequate response to Zarxio before requesting the non‑preferred G‑CSF agent.

    • Requirement applies to new starts only.
    • Does not apply when indication is not shared with Zarxio.
    Billing Rule

    Require generic infliximab/Remicade trial for infliximab biosimilars

    For Avsola, Inflectra, or Renflexis new starts, document trial and inadequate response to generic infliximab or Remicade before requesting the non‑preferred infliximab biosimilar.

    • Requirement applies to new starts only.
    • Does not apply when indication is not shared with generic infliximab or Remicade.
    Billing Rule

    Require Tyruko trial for Tysabri new starts

    For natalizumab (Tysabri) new starts, document trial and inadequate response to Tyruko; the step does not apply when the indication is not shared with Tyruko.

    • Requirement applies to new starts only.
    • Document indication differences to support exemption.
    Billing Rule

    Require Udenyca trial for non‑preferred pegfilgrastim products

    For non‑preferred pegfilgrastim biosimilar or Ryzneuta new starts, document trial and inadequate response to Udenyca prior to approval.

    • Requirement applies to new starts only.
    • Does not apply when indication is not shared with preferred pegfilgrastim products.
    Billing Rule

    Require Riabni/Ruxience before Rituxan/Truxima

    For Rituxan, Rituxan Hycela, or Truxima new starts, require trial and inadequate response to Riabni or Ruxience before approving the non‑preferred rituximab product.

    • Requirement applies to new starts only.
    • Exemption when indication is not shared with Riabni/Ruxience.
    Billing Rule

    Require Kanjinti or Trazimera trial for trastuzumab products

    For Herceptin and trastuzumab biosimilar new starts, document trial and inadequate response to Kanjinti or Trazimera before approving Herceptin or a non‑preferred trastuzumab biosimilar.

    • Requirement applies to new starts only.
    • Does not apply when indication is not shared with the preferred agents.
    Note
    Note
    Note

    inv cu-190: Evkeeza initial therapy

    Evkeeza initial therapy — new starts

    Evkeeza initial therapy: Trial and failure of or contraindication to both a maximally-tolerated statin and a PCSK9 inhibitor required for approval.new starts only

    inv cu-191: Invega Hafyera

    Invega Hafyera initial therapy requirements

    Invega Hafyera initial: At least 4 months of 1-month paliperidone palmitate treatment OR at least one 3-month paliperidone palmitate injection must be documented.4 months or 1 three-month injection

    Applies to new starts only

    inv cu-192: Invega Trinza

    Invega Trinza initial therapy requirements

    Invega Trinza initial: At least 4 months of 1-month paliperidone palmitate treatment must be documented.4 months

    Applies to new starts only

    inv cu-193: Initial therapy requirements (collection)

    Initial therapy (new starts) requirements:

    Intravitreal agents: Prior trial and inadequate response to bevacizumab required; additional second-step anti-VEGF trial required for certain agents.new starts only

    See intravitreal-specific entries

    Rituximab agents: Prior trial and failure of Riabni or Ruxience required for other rituximab products.new starts only

    See rituximab-specific entry

    inv cu-194: Initial therapy requirement

    Requirement for new starts

    Prior injectable corticosteroid trial: New start must have tried and failed at least one other injectable corticosteroid.>=1 injectable corticosteroid

    Applies to new starts only